Psoriasis flare drug study pulled before it began
NCT ID NCT06886009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It was a regulatory requirement to monitor real-world use after the drug's launch in Korea.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Spesolimab (Spevigo®)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ajou University Hospital
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, 05505, South Korea
-
Pusan National University Yangsan Hospital
Busan, 49241, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Costa rica launches national registry to track rare skin disease
- New registry aims to unlock secrets of rare skin disease GPP
- New injection aims to stop dangerous psoriasis flares in their tracks
- New drug spesolimab under Real-World watch for rare skin disease
- New pill shows promise for rare, severe psoriasis
- Can a single infusion stop GPP flares in their tracks?